DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wttrrt/biologicals_in) has announced the addition of the "Biologicals in Oncology Drug Pipeline Update 2013" report to their offering.
This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.
There are today 881 companies plus partners developing 1527 biological drugs in 3359 developmental projects in cancer. In addition, there are 24 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 889 drugs.
Identified drugs are linked to 604 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 82 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Investigators
Includes more than 881 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Developmental stage
This Drug Pipeline Update contains 1527 biological drugs in development, which have a total of 3359 developmental projects in cancer. In addition there are suspended and ceased drugs.
For more information visit http://www.researchandmarkets.com/research/wttrrt/biologicals_in
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
